Beovu® (brolucizumab) is a prescription drug injected directly into the eye for the treatment of “wet”, Age-related Macular Degeneration; a leading cause of blindness. Manufactured by Novartis, the drug was first approved by the U.S. Food & Drug Administration in October of 2019. Patients treated with Beovu usually receive an injection once a month for the first three months of treatment, with subsequent injections every 8 to 12 weeks thereafter.
However, instead of improvement of their Macular Degeneration, Beovu users have developed Retinal Vasculitis (RV) and/or Retinal Vascular Occlusion (RVO), inflammatory eye conditions that cause loss of vision and can lead to blindness. In essence, the retinas become inflamed and symptoms such as redness, blurred vision, onset of color-blindness or light sensitivity, or an increase in “floaters” (small dark spots and strings in one’s field of vision) begin to develop. In June of 2020, after this frightening association was reported by the American Society of Retina Specialists, the FDA approved a label change to warn of the newfound danger.
More recently, in November of 2020, the American Academy of Ophthamology also noted the association between Beovu use and development of RV and RVO. Even Novartis suggests people who have received Beovu injections to seek immediate care from a physician if they develop symptoms of RV or RVO.
We are currently investigating Beovu cases Nationwide. If you or someone you know has been diagnosed with Retinal Vasculitis (RV) and/or Retinal Vascular Occlusion (RVO) after treatment with Beovu, contact us online or call us at 1-866-252-3535.
Do not stop taking any medication without consulting your healthcare provider.